OR WAIT 15 SECS
The new US offices will give the company the ability to support its US-based customers on site while continuing to collaborate with its global team.
Leukocare, a German biotechnology company, announced on Jan. 11, 2021 that it has officially launched its development laboratories and offices in Milford, MA.
According to a company press release, the new US offices will give the company the ability to support its US-based customers on site while continuing to collaborate with its global team. The offices and laboratories are located on Rentschler Biopharma´s Milford premises, where the companies will continue to carry out their global strategic alliance that was established in 2017.
“I am delighted to announce the opening of Leukocare´s US site today,” said Michael Scholl, CEO at Leukocare, in the press release. “The company´s outstanding development over the last few years led to our desire of establishing a presence in the largest pharmaceuticals market worldwide. This strategic step enables us to be even closer to both our US and global customers and to better understand and serve their needs. Furthermore, the existing infrastructure of Rentschler in Milford—that we will partially make use of—allows us to start operations without any delay and, thus, makes Milford the perfect choice for our newly established US site. We therefore will continue to pursue our strategy of pushing boundaries of biopharmaceutical product development by combining innovative biostatistics, artificial intelligence, and vast formulation expertise with first-class analytics.”